Annual report pursuant to Section 13 and 15(d)

Related Party Agreements (Narrative) (Details)

v3.21.1
Related Party Agreements (Narrative) (Details)
 12 Months Ended
Jun. 11, 2020
USD ($)
Apr. 30, 2019
USD ($)
Mar. 29, 2019
shares
Jan. 01, 2017
USD ($)
shares
Jul. 26, 2016
USD ($)
shares
Jul. 22, 2016
Mar. 13, 2015
Dec. 31, 2020
USD ($)
item
shares
Dec. 31, 2019
USD ($)
shares
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares - Public Offering               $ 37,230,000 $ 31,625,000
Preferred stock voting rights multiplier         1.1        
At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares - Public Offering               $ 59,800,000 $ 22,500,000
Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from issuance of common shares - Public Offering $ 37,200,000 $ 31,600,000              
Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Issuance of common shares - Founders Agreement (in shares) | shares               1,206,667 709,314
Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Shares issuable on conversion, per share converted | shares         1        
Fortress Biotech, Inc [Member]                  
Related Party Transaction [Line Items]                  
Proceeds from related party debt         $ 2,000,000.0        
Percentage of fully diluted equity         2.50% 2.50%   2.50% 2.00%
Expenses from related party transaction               $ 500,000 $ 500,000
Founders agreement term         15 years        
Agreement renewal term         1 year        
Paid in kind dividend, period prior to payment date for measuring ownership         1 day        
Equity fee, period for payment after financing               5 days  
Equity fee payable in shares (as a percent)               2.50%  
Cash fee (as a percent)               4.50%  
Cash fee, period for payment               90 days  
Change in control fee, multiplier | item               5  
Change in control fee, measurement period               12 months  
Change in control fee, specified rate component               4.50%  
MSA agreement term             5 years    
Annual consulting fee               $ 500,000  
Consulting fee when net assets exceed threshold               1,000,000.0  
Net assets threshold               $ 100,000,000  
Fortress Biotech, Inc [Member] | Issuance Related to Debt Financing [Member]                  
Related Party Transaction [Line Items]                  
Issuance of common shares - Founders Agreement (in shares) | shares     108,069           108,069
Percentage of fully diluted equity     2.50%           2.50%
Fortress Biotech, Inc [Member] | At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Issuance of common shares - Founders Agreement (in shares) | shares               342,773 87,656
Proceeds from issuance of common shares - Public Offering               $ 59,800,000 $ 22,500,000
Issuance of common shares recorded (in shares) | shares               101,632  
Percentage of fully diluted equity               2.50% 2.50%
Fortress Biotech, Inc [Member] | Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Issuance of common shares - Founders Agreement (in shares) | shares               286,390 197,656
Proceeds from issuance of common shares - Public Offering               $ 37,200,000 $ 31,600,000
Percentage of fully diluted equity               2.50% 2.50%
Fortress Biotech, Inc [Member] | General and Administrative [Member] | Issuance Related to Debt Financing [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction               $ 400,000  
Fortress Biotech, Inc [Member] | General and Administrative [Member] | At the Market Offering [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction               1,500,000 $ 500,000
Fortress Biotech, Inc [Member] | General and Administrative [Member] | Public Offering [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction               900,000 800,000
Fortress Biotech, Inc [Member] | Common Shares [Member]                  
Related Party Transaction [Line Items]                  
Number of shares issued in conversion | shares         7,000,000.0        
Fortress Biotech, Inc [Member] | Preferred Class A [Member]                  
Related Party Transaction [Line Items]                  
Percentage of fully diluted equity           2.50%      
Number of shares issued in conversion | shares         250,000        
Director [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction               113,000 102,000
Annual consulting fee               50,000  
Value of shares granted as compensation               $ 63,000 $ 52,000
Number of shares granted as compensation | shares               50,000 34,000
Director [Member] | Maximum [Member]                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation               $ 50,000  
Number of shares granted as compensation | shares               10,000  
Board of Directors Chairman [Member]                  
Related Party Transaction [Line Items]                  
Expenses from related party transaction               $ 122,000 $ 105,000
Annual consulting fee       $ 60,000          
Value of shares granted as compensation               $ 62,000 $ 45,000
Number of shares granted as compensation | shares               50,000 34,000
Board of Directors Chairman [Member] | Maximum [Member]                  
Related Party Transaction [Line Items]                  
Value of shares granted as compensation       $ 50,000          
Number of shares granted as compensation | shares       10,000